Full text is available at the source.
End-stage renal diseases associated with SGLT2 inhibitors versus GLP-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease
End-stage kidney disease linked to SGLT2 inhibitors versus GLP-1 receptor agonists in fatty liver disease with metabolism problems
AI simplified
Abstract
SGLT2 inhibitors are associated with a 33% lower risk of end-stage renal disease compared to GLP-1 receptor agonists in patients with chronic kidney disease.
- In patients without chronic kidney disease, SGLT2 inhibitors showed a 68% reduced risk of end-stage renal disease compared to GLP-1 receptor agonists.
- Incidence rates of end-stage renal disease were 20.3 events per 1,000 person-years for SGLT2 inhibitors and 30.0 for GLP-1 receptor agonists in the chronic kidney disease cohort.
- For those without chronic kidney disease, the incidence rates were 0.9 events per 1,000 person-years for SGLT2 inhibitors and 2.5 for GLP-1 receptor agonists.
- The findings suggest that the use of SGLT2 inhibitors may provide renal protection in patients with metabolic dysfunction-associated steatotic liver disease, regardless of chronic kidney disease status.
AI simplified